May 6th 2024
Darolutamide has been adopted routinely in clinical practice as a component of both doublet and triplet regimens for the treatment of patients with metastatic hormone-sensitive prostate cancer.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
CAR T-Cell Use Possible in Metastatic Castration-Resistant Prostate Cancer
March 7th 2022In an interview with Targeted Oncology, Tanya Dorff, MD, discussed the exploration of chimeric antigen receptor T-cell therapy in prostate cancer, including recent findings from a phase 1 clinical trial.
Read More
Part 1: Deciding Whether Next-Generation Scans Are Needed for nmCRPC
February 18th 2022During a live event, Evan Yu, MD, discussed how to monitor a patient being treated with androgen deprivation therapy and hormonal agents for nonmetastatic castration-resistant prostate cancer using prostate-specific antigen levels and next-generation imaging.
Read More
PFS Prolonged With Continuous Enzalutamide After AR Inhibitor Progression in mCRPC
February 18th 2022According to results from the phase 3b PRESIDE trial, use of continuous enzalutamide may extend progression-free survival in men with chemotherapy-naïve metastatic castration-resistant prostate cancer.
Read More
Upfront Olaparib/Abiraterone Achieves Significant rPFS Benefit in mCRPC
February 18th 2022A significant percentage of reduction in the risk of radiographic disease progression or death was observed with olaparib plus abiraterone compared with placebo and abiraterone in patients with metastatic castration resistant prostate cancer.
Read More
Deep PSA Response With Apalutamide Linked to HRQOL Improvement in Advance Prostate Cancer
February 17th 2022A look back at apalutamide treatment in the the TITAN and SPARTAN trials showed that deep prostate-specific antigen responses lead to improvement in certain health-related quality of life factors.
Read More
First PSMA PET Set to Improve Imaging in the Prostate Cancer Field
February 15th 2022In an interview with Targeted Oncology, Bridget Koontz, MD, United States chief medical officer and deputy global chief medical officer at GenesisCare, discusses 18F-DCFPyL and how the well-tolerated agent can change the way prostate cancer patients are treated
Read More
Positive Results Correlate With Use of Darolutamide in nmCRPC
February 10th 2022In an interview with Targeted Oncology, Neal Shore discusses the findings of ARAMIS which looked at darolutamide in men with high-risk non-metastatic castration-resistant prostate cancer, and its primary end point of metastasis-free survival.
Read More
Roundtable Discussion: Aghalar and Vaena Look at The role of Cabazitaxel in CRPC
February 1st 2022During a Targeted Oncology live event, Jahan Aghalar, MD, and Daniel Vaena, MD, discussed the results of trials of cabazitaxel in patients with castration-resistant prostate cancer and how to manage toxicity of the therapy.
Read More